MERZ

31.1.2020 09:04:13 CET | Business Wire | Press release

Merz Aesthetics Presents Data at the IMCAS World Congress 2020

Merz, a global leader in medical aesthetics, announced today that data on the Merz Aesthetics product portfolio, including Belotero^® , Cellfina^® and Radiesse^® will be featured in oral and poster presentations at the 2020 International Master Course on Aging Science (IMCAS) World Congress, to be held from 30 January to 1 February 2020 in Paris, France.

“This meeting provides a platform for Merz Aesthetics to not only foster education and continuous training but also, to engage in thoughtful industry conversations while connecting with medical aesthetics physicians and fellow industry leaders from around the world,” said Bob Rhatigan, CEO of Merz Aesthetics. “We are grateful that our heritage and innovation in this space allows us to partner with world-renowned medical aesthetic experts, to share research on the diversified Merz Aesthetics product portfolio at the IMCAS World Congress.”

In addition to the poster presentations listed below, Merz Aesthetics is sponsoring the symposium event “Facial Rejuvenation: Interactive Sessions to Level-Up Your Injection Skills”, to be held on Saturday, 1 February at 10.30h – 12.30h, Room Amphi Bleu . The session will be opened by Bob Rhatigan, CEO of Merz Aesthetics and will include treatment insights from four international expert speakers:

Dr. Tatjana Pavicic – Dermatologist, Germany
Dr. Kate Goldie – Aesthetic Physician, United Kingdom
Prof. Yana Yutskovskaya – Dermatologist, Russia
Dr. Jani van Loghem – Aesthetic Physician, Netherlands

Oral Presentations

Independent presentations including data on the Merz Aesthetics portfolio:

What’s new in minimally invasive treatments

Update on dermal fillers (99921) – Kate Goldie, MBChB – UK. Thursday, 30 January, 17.54 – 18.06h, Amphi Bleu – Level 2

Body shaping and cellulite

Cellulite and skin laxity (93276). Doris Hexsel, Dermatologist – Brazil. Thursday, 30 January, 10.30 – 10.42h, Amphi Bleu – Level 2
Cellulite treatment update: how dimples, laxity and volume can be effectively treated (98147)¹ . Gabriela Casabona, MD– Spain. Thursday, 30 January, 11.18 – 11.30h, Amphi Bleu – Level 2

Biostimulatory fillers

Biostimulators: how dilution/diffusion interferes with outcome (93391). Gabriela Casabona, MD – Spain. Saturday, 1 February, 16.30 – 16.42, Room 143 - Level 1

E-Poster Presentations

E-Posters will be available for viewing at the Poster Zone on Level 2 , from Thursday, 30 January to Saturday, 1 February 2020 .

Distribution of cohesive polydensified matrix cross-linked hyaluronic acid volumizing gel in ex vivo human skin model. Christina Wollenburg, Jeanette Simon, Dr. Kay Marquardt, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Calcium hydroxylapatite microspheres provide organization into unorganized collagen networks leading to improvement of skin attractiveness. Gabriela Casabona, MD – Spain. Dr. Bartosch Nowag, Daniela Schäfer, Davide Greco, Dr. Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.

BOCOUTURE^® Milestone

This year, Merz is also celebrating the ten-year anniversary of BOCOUTURE^® (incobotulinumtoxin A) in Europe. The botulinum toxin is part of the Merz Aesthetics portfolio and has received approval in 15 countries in Europe within the last ten years. A Booth Talk about “BOCOUTURE^® - 10 Years of a Unique Neurotoxin” with Dr. Thomas Rappl will take place Friday, 31 January, 16.00, Booth N° P251 .

About Merz

Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,213 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com .

¹ Merz supported Investigator Initiated Trials

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005133/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom